ReShape Lifesciences® Secures International Patent for Diabetes Neuromodulation Technology
Tuesday, February 04, 2025
ReShape Lifesciences® has received a key international patent from the Israel Patent Office for its Diabetes Neuromodulation technology.
Diabetes Bloc-Stim Neuromodulation™ (DBSN™), the ReShape Diabetes Neuromodulation system is a minimally invasive therapeutic implant concept. It delivers bioelectronic neuromodulation to vagus nerve branches that regulate blood glucose levels.
The system stimulates vagus celiac fibres in the pancreas to enhance insulin release while blocking hepatic vagal branches in the liver to reduce glucose production and insulin resistance.
This approach utilises a proprietary, reversible, and adjustable electrical blockade, representing a potential step forward in personalised diabetes treatment. ReShape Lifesciences believes that its system offers advantages over standalone vagus nerve stimulation, which has shown variable results in previous research.
The patent, numbered 277949 and titled Simultaneous Multi-Site Vagus Nerve Modulation for Improved Glycemic Control Systems and Methods, will remain valid until 4 December 2039.
The Diabetes Neuromodulation system integrates the company’s proprietary vagus nerve block (vBloc™) technology with vagus nerve stimulation to manage Type 2 diabetes, a condition often linked to obesity.
The technology is designed to help reduce dependency on medication, lower treatment costs, and address complications arising from poor blood sugar control and non-adherence to treatment plans.
The patent strengthens ReShape’s intellectual property portfolio, which includes 62 issued or pending patents covering vagal neuromodulation, glucose control, artificial intelligence, and Bluetooth applications.
This extensive portfolio supports the company’s commercialisation plans while offering protection against potential competition.
Type 2 diabetes remains a widespread health issue that is difficult to manage despite available treatments such as medication, surgery, and dietary changes.
ReShape’s Diabetes Neuromodulation technology works by selectively modulating vagal nerve activity to influence the liver and pancreas. Preclinical studies using Zucker rat and alloxan-treated swine models of Type 2 diabetes have shown improvements in blood glucose control.
The system uses bioelectronics to enhance insulin production and regulate blood sugar levels in a personalised manner, with potential applications in both Type 2 diabetes and hypoglycaemia treatment.
Source: reshapelifesciences.com
